SG10201609673QA - Compositions And Methods For Modulating Metabolic Pathways - Google Patents

Compositions And Methods For Modulating Metabolic Pathways

Info

Publication number
SG10201609673QA
SG10201609673QA SG10201609673QA SG10201609673QA SG10201609673QA SG 10201609673Q A SG10201609673Q A SG 10201609673QA SG 10201609673Q A SG10201609673Q A SG 10201609673QA SG 10201609673Q A SG10201609673Q A SG 10201609673QA SG 10201609673Q A SG10201609673Q A SG 10201609673QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
metabolic pathways
modulating metabolic
modulating
Prior art date
Application number
SG10201609673QA
Other languages
English (en)
Inventor
Michael Zemel
E Douglas Ii Grindstaff
Antje Bruckbauer
Original Assignee
Numeta Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numeta Sciences Inc filed Critical Numeta Sciences Inc
Publication of SG10201609673QA publication Critical patent/SG10201609673QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
SG10201609673QA 2011-07-15 2012-07-13 Compositions And Methods For Modulating Metabolic Pathways SG10201609673QA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161508139P 2011-07-15 2011-07-15
US201261636597P 2012-04-20 2012-04-20
US201261636605P 2012-04-20 2012-04-20
US201261636608P 2012-04-20 2012-04-20
US201261636610P 2012-04-20 2012-04-20
US201261636598P 2012-04-20 2012-04-20
US201261636603P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
SG10201609673QA true SG10201609673QA (en) 2017-01-27

Family

ID=47519040

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201609673QA SG10201609673QA (en) 2011-07-15 2012-07-13 Compositions And Methods For Modulating Metabolic Pathways

Country Status (15)

Country Link
US (9) US8617886B2 (zh)
EP (2) EP3466418A1 (zh)
JP (2) JP6158801B2 (zh)
KR (1) KR20140054066A (zh)
CN (3) CN108114285A (zh)
AU (2) AU2012284267B2 (zh)
BR (1) BR112014000895A2 (zh)
CA (1) CA2841748C (zh)
HK (3) HK1198925A1 (zh)
IL (1) IL230467B (zh)
MX (1) MX2014000419A (zh)
RU (2) RU2631597C2 (zh)
SG (1) SG10201609673QA (zh)
WO (1) WO2013012760A1 (zh)
ZA (1) ZA201400553B (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP2875359A4 (en) * 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
ES2938843T3 (es) * 2013-01-18 2023-04-17 Mans Jean Pierre Composición que comprende urolitina B y testosterona, leucina y/o creatina para el crecimiento muscular
MX370090B (es) 2013-02-01 2019-10-25 Centro De Investig En Alimentacion Y Desarrollo A C Un método y un sistema para el tratamiento integral de aguas residuales de una industria del maíz.
SG11201507390SA (en) * 2013-03-14 2015-10-29 Abbott Lab Treatment of insulin resistance associated with prolonged physical inactivity
RU2015143836A (ru) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Лейцин и никотиновая кислота для снижения уровня липидов
US20160000737A1 (en) * 2013-03-15 2016-01-07 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
BR112016007487A2 (pt) 2013-10-09 2017-08-01 Nestec Sa composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
AU2015222754B2 (en) * 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
AU2015237273B2 (en) 2014-03-27 2020-06-18 Roland W. Winterfield Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
JP6309343B2 (ja) * 2014-05-21 2018-04-11 協和発酵バイオ株式会社 ３−ヒドロキシ−３−メチル酪酸カルシウム含有錠剤およびその製造方法
WO2016049236A1 (en) * 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
ITMI20141843A1 (it) * 2014-10-27 2016-04-27 Giovannini Luca Associazioni sinergiche stimolanti l¿espressione di sirtuina 1
EP3233188A4 (en) * 2014-12-19 2018-11-07 Halo Life Science, LLC Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels
WO2016115050A1 (en) 2015-01-12 2016-07-21 Lagunita Llc Micro-droplet delivery device and methods
JP2018513106A (ja) * 2015-03-03 2018-05-24 ネステク ソシエテ アノニム エネルギー消費の促進に使用するための化合物
CN104771327B (zh) * 2015-03-11 2017-09-12 广州健坤生物科技有限公司 一种具有激活hsf‑1转录功能的组合物及其用途
WO2016151372A1 (en) * 2015-03-21 2016-09-29 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2016164830A1 (en) 2015-04-10 2016-10-13 Lagunita Llc Piezoelectric dispenser with replaceable ampoule
PT3302704T (pt) * 2015-06-01 2023-02-13 Metabolic Tech Llc Composições e métodos de utilização de beta-hidroxi-beta-metilbutirato (hmb) para diminuir a massa gorda
US10285963B2 (en) * 2015-06-08 2019-05-14 Horacio Astudillo de la Vega Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
AU2016323779B2 (en) * 2015-09-16 2022-03-17 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US11701336B2 (en) 2015-10-30 2023-07-18 Yasumasa Kato Method of determining composition effective for treating diabetes
CN108348495A (zh) * 2015-10-30 2018-07-31 加藤恭正 糖尿病治疗用组合物
CN106854643B (zh) * 2015-12-08 2021-01-26 台湾粒线体应用技术股份有限公司 植物萃取物用于提升粒线体活性的用途
BR122023026038A2 (pt) * 2016-01-21 2024-01-16 Metabolic Technologies, Inc. Usos de um ácido e de um modulador de autofagia e de lipofagia
US11406609B2 (en) 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
RU2018145520A (ru) * 2016-05-25 2020-06-25 ТиЭсАй ГРУП ЛТД. Стабилизация композиций бета-гидроксиизовалериановых кислот в мягких гелевых капсулах
CA3039106A1 (en) 2017-01-20 2018-07-26 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
JP6895309B2 (ja) * 2017-05-11 2021-06-30 理研ビタミン株式会社 Ａｍｐｋ活性促進用組成物
WO2019084451A1 (en) * 2017-10-26 2019-05-02 Shukla Vershalee HYPOGLYCEMIC AGENTS FOR ORAL TAKING AS ADDITIVES AND FOOD SUPPLEMENTS
JP7436363B2 (ja) 2017-12-08 2024-02-21 ノバルティス アーゲー 流体送達アライメントシステム
CN108324929B (zh) * 2018-03-09 2021-07-13 深圳市容大生物技术有限公司 一种减少体脂率及体脂反弹的组合物及其制备方法和应用
CN108642001B (zh) * 2018-05-08 2022-09-02 中国农业科学院北京畜牧兽医研究所 一种提高牛性控冻精体外受精能力的方法
CN108837154B (zh) * 2018-08-31 2021-05-07 中国药科大学 一种细胞膜仿生脂蛋白靶向纳米递药系统的制备及应用
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
CN109517848A (zh) * 2018-11-01 2019-03-26 沈阳农业大学 具有抗灰葡萄孢菌活性的dhis的制备方法和应用
WO2020092877A1 (en) * 2018-11-02 2020-05-07 The Children's Hospital Of Philadelphia Modulation of mitochondrial biogenesis by increase in iron sulfur cluster activity
CN109521118A (zh) * 2018-12-18 2019-03-26 广西壮族自治区兽医研究所 一种同时测定桃金娘果中4种酚类物质的方法
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
WO2020251977A1 (en) 2019-06-11 2020-12-17 Dremcubed, Llc Nutraceutical formulation for unblocking receptors
WO2021096882A1 (en) * 2019-11-11 2021-05-20 Nusirt Sciences, Inc. Compositions, methods and kits for altering adipocytes
US20210145764A1 (en) * 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
JP2023512778A (ja) * 2020-02-05 2023-03-29 デイリーカラーズ ヘルス，インコーポレイテッド 栄養補助食品の組成物および方法
IL297215A (en) 2020-04-17 2022-12-01 Kedallon Therapeutics Inc A hydrodynamically activated preservative free distribution system
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2022049433A1 (en) * 2020-09-04 2022-03-10 Societe Des Produits Nestle Sa Compositions and methods for providing health benefits in an animal
CN112836621B (zh) * 2021-01-29 2022-11-08 华东理工大学青岛创新研究院 一种植物细胞表型检测方法及系统
EP4294405A1 (en) * 2021-02-21 2023-12-27 Pharma Cinq, LLC Compositions and compounds for co-delivery of uridine and ketoleucine
WO2023025101A1 (en) * 2021-08-26 2023-03-02 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Composition and method for enhancing mitochondrial biogenesis and activating pgc-1α
WO2023048878A1 (en) * 2021-09-24 2023-03-30 The Trustees Of Indiana University Depletion of fndc5 reduces cancer induced muscle loss/cachexia
CN113698384B (zh) * 2021-10-26 2022-01-18 上海维京生物医药科技有限公司 阿格列汀没食子酸盐及其制备方法和应用

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007650A (en) 1911-05-13 1911-10-31 Wesley Ellis Belt-guide.
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
JPH03219838A (ja) 1989-11-06 1991-09-27 Itochu Shiryo Kk 体脂肪の蓄積量を減少させる飼料
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
NZ256300A (en) * 1992-09-16 1997-06-24 Univ Iowa State Res Found Inc Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
EP0873754B1 (en) 1996-01-09 2003-07-30 Riken Amino acid compositions
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE69707413T3 (de) 1997-01-09 2009-07-02 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
CN1305485A (zh) 1998-05-04 2001-07-25 安德里斯·约翰尼斯·凯塞尔 单体,寡聚和多聚科诺威纳格尔缩合产物
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
ES2250112T3 (es) 1999-03-08 2006-04-16 Medicure Inc. Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6.
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
WO2001021165A1 (en) 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
EP1250052A1 (en) 2000-01-25 2002-10-23 Juvenon, Inc. Nutritional supplements for aged pets
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
EP2363061A1 (en) 2000-06-16 2011-09-07 BodyMedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
JP2002047699A (ja) 2000-07-31 2002-02-15 Toto Ltd 給水の配管システム
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
TWI329516B (en) 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
WO2002052951A1 (en) 2000-12-29 2002-07-11 Martin Francis Gannon An animal food product
WO2002071874A2 (en) 2001-03-09 2002-09-19 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
JP2005514921A (ja) 2001-11-09 2005-05-26 ダナ−ファーバー キャンサー インスティチュート インク ＰＧＣ−１β、新規ＰＧＣ−１相同体およびその用途
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
US20040009216A1 (en) 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
CA2490544C (en) 2002-06-26 2011-04-19 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20050181097A1 (en) 2002-09-16 2005-08-18 Mars, Inc. Nutritionally complete pet food and method of feeding and manufacturing same
RU2335927C2 (ru) 2002-09-20 2008-10-20 Новартис Аг Обогащенные лейцином питательные композиции
WO2004032715A2 (en) 2002-10-09 2004-04-22 Bodymedia, Inc. Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
WO2004082401A1 (en) * 2003-03-13 2004-09-30 Red Arrow Products Co., Llc. Browning composition for application to a film for holding a food product
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
EP1605781A1 (en) 2003-03-18 2005-12-21 Novartis AG Compositions comprising fatty acids and amino acids
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
ATE390142T1 (de) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
FR2856407B1 (fr) 2003-06-19 2007-10-12 Inst Nat Sante Rech Med Procede de production d'une proteine recombinante d'interet et proteine produite
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
JP5174348B2 (ja) 2003-09-12 2013-04-03 ボディーメディア インコーポレイテッド 心臓関連状態パラメータのモニター方法及び装置
EP1987723B1 (en) 2003-11-03 2012-03-07 Hill's Pet Nutrition, Inc. Coated pet food composition
EP1685133A1 (en) 2003-11-19 2006-08-02 DSM IP Assets B.V. Manufacture of vitamin b6
WO2005049006A1 (ja) * 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
WO2005053422A2 (en) 2003-11-26 2005-06-16 Hill's Pet Nutrition, Inc. Method to reduce odor of excreta from companion animals
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
MXPA06014587A (es) 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
JP4785140B2 (ja) 2004-08-04 2011-10-05 国立大学法人東京海洋大学 脂質代謝調節作用を有する食品素材、健康食品、動物用飼料及び動物の飼育方法
US8299083B2 (en) 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
CA2578197C (en) 2004-08-24 2010-06-29 Depuy Mitek, Inc. Expandable needle suture apparatus and associated handle assembly with rotational suture manipulation system
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
US20080004335A1 (en) 2004-11-29 2008-01-03 Kinya Takagaki Athletic Ability Enhancing Composition
EP1832284A4 (en) * 2004-12-28 2008-07-30 Ajinomoto Kk INDUCER OR SECRETAGOGUE OF ADIPONECTIN
AU2006206274A1 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
DE602006004963D1 (de) 2005-02-11 2009-03-12 Argenta Discovery Ltd Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
CA2599989A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1890709B1 (en) 2005-05-13 2011-11-09 Nestec S.A. Production of glucosamine from plant species
EP1898890A1 (en) 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2007039367A (ja) 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
CA2617532A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007041643A1 (en) 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
CN101316582A (zh) 2005-11-30 2008-12-03 雀巢技术公司 治疗肌肉损失的方法
US20090136588A1 (en) 2005-12-02 2009-05-28 Hill's Pet Nutrition, Inc. Methods For Altering Food Intake, Modifying Nutrient Digestibility and Altering Stool Quality and/or Stool Frequency
CN104606228A (zh) 2005-12-02 2015-05-13 希尔氏宠物营养品公司 改变粪便质量和/或粪便频率的方法
JPWO2007069744A1 (ja) * 2005-12-16 2009-05-28 味の素株式会社 メタボリックシンドローム予防・改善用組成物
BRPI0706448A2 (pt) 2006-01-10 2011-03-29 Hills Pet Nutrition Inc método, composição e kit para promover perda de gordura em um animal adulto, meio para comunicar informação sobre ou instruções para usar uma dieta, e, uso de lisina
AU2007221245A1 (en) 2006-02-28 2007-09-07 The Trustees Of Boston University Metabolic regulators and uses thereof
JP5222482B2 (ja) * 2006-04-07 2013-06-26 花王株式会社 脂肪分解促進剤
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
WO2007128461A1 (en) 2006-05-10 2007-11-15 Dsm Ip Assets B.V. Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
EA018258B1 (ru) 2006-07-12 2013-06-28 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенный ациланилид и содержащие его композиции и способы лечения
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
AU2007341981A1 (en) * 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
WO2008089212A1 (en) 2007-01-16 2008-07-24 Ipintl, Llc Novel composition for treating metabolic syndrome
US20090006457A1 (en) 2007-02-16 2009-01-01 Stivoric John M Lifeotypes
BRPI0721343A2 (pt) 2007-02-23 2014-03-18 Hills Pet Nutrition Inc Composição, métodos para prevenir ou tratar obesidade em um animal sem perda concomitante de massa de músculo magro, para a preservação de massa de músculo magro em um animal, e para o ganho de massa de músculo magro em um animal, e, uso das composições.
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US7850997B2 (en) * 2007-03-21 2010-12-14 Tim Romero Dietary compositions and methods of enhancing lean body mass and exercise performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US8242139B2 (en) 2007-04-30 2012-08-14 Abbott Laboratories Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
US20080286254A1 (en) 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
JP5121308B2 (ja) * 2007-05-28 2013-01-16 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善または治療組成物
US20100204204A1 (en) 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
WO2009008991A2 (en) 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
WO2009033034A1 (en) 2007-09-07 2009-03-12 Nike, Inc. Wearable device assembly having athletic functionality
US7820618B2 (en) * 2007-10-04 2010-10-26 Northern Innovations and Formulations Energy status of an individual by enhanced usage of an endogenous fuel source
CA2702471A1 (en) 2007-10-22 2009-04-30 The Coca-Cola Company Neutralized juice-based beverages and method of making same
WO2009054994A2 (en) 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
US20100304003A1 (en) 2007-12-21 2010-12-02 Kim Friesen Pet food composition
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
WO2009100130A1 (en) 2008-02-04 2009-08-13 Mercury Therapeutics, Inc. Ampk modulators
JP5643116B2 (ja) 2008-03-03 2014-12-17 ナイキ イノベイト セー． フェー． 対話型運動器具システム
WO2009117403A1 (en) 2008-03-17 2009-09-24 The Procter & Gamble Company User-customizable dosing system
US8517896B2 (en) 2008-04-02 2013-08-27 Nike, Inc. Wearable device assembly having athletic functionality
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
JP2011528557A (ja) 2008-07-18 2011-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 過体重動物と関連する障害を治療するための組成物および方法
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
AU2009282482B2 (en) 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism
FR2938732B1 (fr) * 2008-11-21 2011-04-01 Holymark Composition nutritive pour sportif, en particulier pour pratiquant d'une activite physique superieure a une heure.
US20100173024A1 (en) * 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CA2929927C (en) 2009-04-26 2018-09-11 Nike Innovate C.V. Gps features and functionality in an athletic watch system
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
AU2010254356A1 (en) 2009-05-28 2011-12-22 Mars, Incorporated Pet food in the form of a coated kibble
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
WO2011003045A1 (en) 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
JP2013500010A (ja) 2009-07-21 2013-01-07 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 愛玩動物の栄養系
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
AU2010295412A1 (en) 2009-09-18 2012-05-03 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
CN102053946B (zh) 2009-10-30 2014-05-28 国际商业机器公司 多核系统中处理请求的数据处理方法、设备和系统
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
HUE032486T2 (en) * 2009-12-18 2018-05-02 Metabolic Tech Inc An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
CN102665704A (zh) 2009-12-29 2012-09-12 希尔氏宠物营养品公司 用于伴侣动物的包含丙酮酸盐的组合物及其使用方法
RU2558540C2 (ru) 2010-01-06 2015-08-10 Нестек С.А. Диетические режимы, пригодные для имитации ограничения калорий
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
JP5865242B2 (ja) 2010-04-28 2016-02-17 日本薬品株式会社 眼精疲労治療用組成物
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
AU2012299126B2 (en) 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
RU2015143836A (ru) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Лейцин и никотиновая кислота для снижения уровня липидов
US20160000737A1 (en) 2013-03-15 2016-01-07 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
EP3054940B1 (en) 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2016049236A1 (en) 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
WO2017040407A1 (en) 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Also Published As

Publication number Publication date
RU2014105552A (ru) 2015-08-27
EP2731599A1 (en) 2014-05-21
KR20140054066A (ko) 2014-05-08
RU2631597C2 (ru) 2017-09-25
US9855235B2 (en) 2018-01-02
US20190224152A1 (en) 2019-07-25
CN103889411B (zh) 2018-03-16
EP3466418A1 (en) 2019-04-10
JP2014520864A (ja) 2014-08-25
US20130017284A1 (en) 2013-01-17
AU2012284267B2 (en) 2017-06-29
US9198883B1 (en) 2015-12-01
WO2013012760A1 (en) 2013-01-24
CN103889411A (zh) 2014-06-25
CN108261547A (zh) 2018-07-10
BR112014000895A2 (pt) 2019-08-06
US8623924B2 (en) 2014-01-07
JP2017160258A (ja) 2017-09-14
US10076507B1 (en) 2018-09-18
HK1198925A1 (zh) 2015-06-19
CN108114285A (zh) 2018-06-05
HK1250656A1 (zh) 2019-01-11
EP2731599A4 (en) 2015-04-08
EP2731599B1 (en) 2018-10-31
US20140148488A1 (en) 2014-05-29
US9072692B2 (en) 2015-07-07
AU2017213477A1 (en) 2017-08-31
ZA201400553B (en) 2018-07-25
US20170312240A1 (en) 2017-11-02
AU2012284267A1 (en) 2014-01-30
US9682053B2 (en) 2017-06-20
US20150342914A1 (en) 2015-12-03
US8617886B2 (en) 2013-12-31
US20160113915A1 (en) 2016-04-28
US9351967B2 (en) 2016-05-31
HK1251146A1 (zh) 2019-01-25
CA2841748A1 (en) 2013-01-24
US20130017283A1 (en) 2013-01-17
IL230467A0 (en) 2014-03-31
JP6158801B2 (ja) 2017-07-05
RU2017129378A (ru) 2019-02-04
US10383837B2 (en) 2019-08-20
IL230467B (en) 2020-07-30
MX2014000419A (es) 2014-09-22
CA2841748C (en) 2021-06-15
US20160338983A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HK1250656A1 (zh) 用於調節代謝途徑的組合物和方法
EP2569429A4 (en) COMPOSITIONS AND METHOD OF METABOLIC MODULATION
HK1203830A1 (zh) 用於治療代謝紊亂的組合物和方法
EP2756084A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
EP2756083A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
PL2755467T4 (pl) Sposoby i kompozycje do kontroli chwastów
EP2756085A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
EP2755987A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
EP2756086A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
EP2755466A4 (en) METHODS AND COMPOSITIONS FOR CONTROLLING WEEDS
EP2755988A4 (en) METHOD AND COMPOSITIONS FOR WEED CONTROL
EP2736330A4 (en) COMPOUNDS AND METHODS
EP2725045A4 (en) POLYMERIZABLE COMPOSITION
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
HK1190936A1 (zh) 治療代謝綜合徵的方法和配方
EP2736329A4 (en) COMPOUNDS AND METHODS
EP2760887A4 (en) COMPOSITIONS AND METHODS OF HEMOSTASE MODULATION
IL250307A0 (en) Pesticide preparations and methods
HRP20160879T1 (hr) Pripravci i postupci za moduliranje kinaze
ZA201308892B (en) Compositions and methods
EP2726110A4 (en) COMPOSITIONS AND METHODS FOR METABOLIC IMAGING
SG11201400491UA (en) Underfill composition
HK1200710A1 (zh) 膽鹼組合物
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR